Our Promise

We will help our partners prevail in their mission to develop needed therapies. We will ensure that high-quality development and imperative urgency remains our focus.

How We Help

Launch Therapeutics offers pharmaceutical and biotech partners a variety of innovative models that provide access to capital, development expertise, and access to additional resources. These models offer an aligned and efficient approach to develop late-stage therapies and accelerate the path to regulatory approval. Launch Tx’s team of experts bring an unrivaled combination of immense commitment, decades of experience, and enthusiastic passion to their work.

Access to Сapital

Bespoke deal structures taking combination of clinical, regulatory, and commercial risks


Team with deep clinical and regulatory expertise with access to an expansive network


Disruptive model accelerating clinical development and regulatory timelines

In The News

Clinical Collaboration Agreement Established between Teva and Launch Therapeutics to Accelerate Development of Dual-Action Asthma Rescue Inhaler (ICS-SABA/TEV-’248) Respiratory Program; Teva and Abingworth Enter Strategic Development Funding Agreement 

  • Collaboration combines Teva’s expertise in respiratory technology development and Launch Therapeutics’ innovative late-stage drug development model to progress Teva’s Dual-Action Asthma Rescue Inhaler (TEV-‘248) program
  • Development funding agreement to provide up to $150 million to offset program costs and to accelerate clinical research for Teva’s TEV-‘248 program in line with Teva’s Pivot to Growth strategy to step up innovation and advance its innovative pipeline
  • Teva’s TEV-‘248 has the potential to be the first Dual-Action Asthma Rescue Inhaler combining an Inhaled Corticosteroid with a Short-Acting Beta-Agonist (ICS-SABA) for both adult and pediatric asthma indications